TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer.

Autor:	Witwicki RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Ekram MB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Qiu X; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Janiszewska M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Shu S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Kwon M; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA., Trinh A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Frias E; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., Ramadan N; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., Hoffman G; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., Yu K; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., Xie Y; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., McAllister G; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., McDonald R; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., Golji J; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., Schlabach M; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., deWeck A; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., Keen N; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., Chan HM; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., Ruddy D; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., Rejtar T; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., Sovath S; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., Silver S; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., Sellers WR; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., Jagani Z; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., Hogarty MD; Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA., Roberts C; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA., Brown M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA., Long H; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Shivdasani RA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Pellman D; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA., Polyak K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: kornelia_polyak@dfci.harvard.edu.
Jazyk:	angličtina
Zdroj:	Cell reports [Cell Rep] 2018 Oct 30; Vol. 25 (5), pp. 1255-1267.e5.
DOI:	10.1016/j.celrep.2018.10.023
Abstrakt:	Perturbed epigenomic programs play key roles in tumorigenesis, and chromatin modulators are candidate therapeutic targets in various human cancer types. To define singular and shared dependencies on DNA and histone modifiers and transcription factors in poorly differentiated adult and pediatric cancers, we conducted a targeted shRNA screen across 59 cell lines of 6 cancer types. Here, we describe the TRPS1 transcription factor as a strong breast cancer-specific hit, owing largely to lineage-restricted expression. Knockdown of TRPS1 resulted in perturbed mitosis, apoptosis, and reduced tumor growth. Integrated analysis of TRPS1 transcriptional targets, chromatin binding, and protein interactions revealed that TRPS1 is associated with the NuRD repressor complex. These findings uncover a transcriptional network that is essential for breast cancer cell survival and propagation. (Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu